… treatment with dapagliflozin for 24 weeks increased plasma PYY levels, and the extent of this
increase was correlated with weight loss, particularly adipose tissue loss, … to weight loss in …

… Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI,
… , compared with those without, and has the additional benefit of causing modest weight loss. …

… add-on treatment of … dapagliflozin was associated with significant weight loss whereas
sulphonylureas were associated with weight gain, and DPP-4 inhibitors were found to be weight …

… , whereby the benefit of this treatment was greater in patients with larger waist … a treatment
anticipated to cause modest weight loss, 15, 16 according to baseline BMI in the Dapagliflozin …

… has an increasing effect on the patient's appetite and weight. However, the weight loss of
our patient continued despite the insulin treatment because her main problem was anorexia. …

… between the estimated and actual weight loss because of dapagliflozin treatment in a
randomized, double-blind, placebo-controlled, cross-over trial. The results showed that …

… Body weight, SBP and triglyceride levels were reduced across most respective subgroups,
with no significant subgroup-by-treatment interactions. For each treatment, weight loss was …

… support this mechanism for weight loss discrepancy seen in … given dapagliflozin, caloric
restriction increased weight loss … therapy strategies to optimize weight loss in these patients. …

… of T1DM, and may be particularly appropriate in patients with T1DM treated with high doses
of insulin or who need weight loss. However, clinical trials in patients with T1DM are still …

… to total weight loss. Daily dapagliflozin was well tolerated with no major difference in adverse
events across treatment groups. The hypoglycemia experience supports the potential for …